The GeparSixto GBG66 trial evaluated the additional effect of carboplatin in NACT containing an anthracycline, a taxane, and a targeted therapy (trastuzumab/lapatinib or bevacizumab) on pCR in patients with stage II–III TNBC and HER2-positive BC. The gene discussed is ERBB2; the disease is breast cancer.